Seribantumab

From WikiProjectMed
Jump to navigation Jump to search
Seribantumab
Monoclonal antibody
Type?
SourceHuman
TargetHER3
Clinical data
Other namesMM-121
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6340H9810N1690O1986S52
Molar mass143151.18 g·mol−1

Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.